	R 2012 Dec 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	15M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	962	1,341	1,196	2,861	2,755	2,845	2,178	2,752	3,316	3,070	3,688	3,890	4,565	4,859
Cost of Operating Revenue	569	807	660	1,775	1,528	1,649	1,321	1,456	1,720	1,934	2,074	2,172	2,384	2,161
Gross Profit	393	534	536	1,086	1,227	1,196	857	1,296	1,595	1,137	1,614	1,718	2,182	2,698
Gross Margin	40.9	39.8	44.8	38.0	44.5	42.0	39.4	47.1	48.1	37.0	43.8	44.2	47.8	55.5
Total Operating Expenses	842	1,146	1,025	2,578	2,354	2,597	2,040	2,386	2,895	3,314	3,546	3,531	3,958	4,136
Operating Profit	120	195	171	283	401	248	138	366	421	-243	142	359	607	723
Operating Margin	12.4	14.6	14.3	9.9	14.6	8.7	6.3	13.3	12.7	-7.9	3.9	9.2	13.3	14.9
Financing Income/(Expense) - Net	-103	-109	-38	-96	-61	-167	-68	-133	-73	-23	-142	-240	-198	-179
Profit before Taxes	725	92	149	161	343	80	62	55	275	-653	-286	-115	487	669
Income Taxes	11	41	53	42	63	6	-27	11	32	-178	-55	29	78	94
Profit after Tax	1,572	1,767	845	109	400	665	325	36	268	-460	-203	-71	3,593	556
PAT Margin	163.5	131.8	70.7	3.8	14.5	23.4	14.9	1.3	8.1	-15.0	-5.5	-1.8	78.7	11.4
EPS - Basic - ex Extraordinary Items	121.47	-39.34	0.26	15.94	26.13	6.08	9.38	5.49	28.40	-51.28	-24.56	-13.21	44.05	60.34
EPS - Diluted - ex Extraordinary Items	121.47	-39.34	0.16	15.85	26.08	6.08	10.71	5.68	28.37	-51.28	-24.56	-13.21	44.05	60.34
EBIT	120	195	171	283	401	248	138	366	421	-243	142	359	607	723
EBITDA	246	349	235	414	527	398	256	540	622	-13	385	580	799	925
EBITDA Margin	25.6	26.0	19.7	14.5	19.1	14.0	11.7	19.6	18.8	-0.4	10.4	14.9	17.5	19.0

Balance Sheet

Abridged

Understanding Balance Sheet

Strides Pharma Science Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Dec 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1,411	1,309	1,445	3,515	3,792	2,484	3,049	2,372	2,817	3,362	3,243	2,969	3,099	3,613
Long-Term Investments	-	42	147	119	102	85	91	491	623	25	73	28	359	388
Property Plant & Equipment - Net	1,056	438	470	1,235	1,183	987	1,137	1,464	1,499	1,514	1,373	959	980	1,154
Total Non-Current Assets	3,387	790	1,036	3,941	4,482	4,225	4,931	3,780	4,198	3,614	3,395	2,871	2,950	3,314
Total Assets	4,798	2,099	2,481	7,456	8,274	6,708	7,980	6,152	7,015	6,976	6,638	5,840	6,049	6,927
Total Current Liabilities	1,797	707	1,002	1,892	3,104	1,899	2,662	2,545	2,738	3,412	2,990	2,879	2,592	2,895
Long Term Debt	731	276	253	2,627	1,638	1,551	1,807	858	1,093	1,022	1,343	743	623	604
Total Non-Current Liabilities	902	309	309	2,856	2,283	2,191	2,516	1,012	1,463	1,181	1,475	889	871	882
Total Liabilities	2,699	1,017	1,311	4,748	5,387	4,090	5,178	3,557	4,201	4,593	4,466	3,768	3,462	3,778
Total Shareholders' Equity	2,026	1,007	1,156	2,658	2,754	2,464	2,649	2,527	2,777	2,359	2,212	2,126	2,552	3,108
Minority Interest	72	76	14	50	134	155	153	67	37	24	-39	-54	35	42
Total Equity	2,098	1,082	1,170	2,708	2,887	2,618	2,802	2,595	2,814	2,383	2,173	2,072	2,586	3,149
Total Liabilities & Equity	4,798	2,099	2,481	7,456	8,274	6,708	7,980	6,152	7,015	6,976	6,638	5,840	6,049	6,927

Cash Flow

Abridged

Understanding Cash Flow Statement

Strides Pharma Science Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Dec 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	15M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	281	-200	156	338	315	-460	-84	390	663	-215	266	449	-2,567	640
Working Capital - Increase/(Decrease)	-311	-261	-96	-342	-341	-191	-323	-326	-328	-190	-458	-79	-164	-100
Net CF from Operating Activities	-29	-461	60	-4	-26	-650	-407	63	335	-405	-191	370	-2,731	539
Capital Expenditures - Net	333	464	241	366	675	399	316	146	294	68	88	29	174	412
Net CF from Investing Activities	772	4,047	37	-2,269	-950	15	-580	-6	-537	-138	277	-158	-103	-178
Dividends Paid - Cash - Total	12	2,990	655	25	43	44	18	154	18	22	-	14	23	37
Stock - Issuance/(Retirement) - Net	79	26	3	1,226	17	4	5	1	4	4	38	53	6	0
Debt - LT & ST - Issuance/(Retirement) - Total	-848	144	321	1,911	604	-711	408	-1,384	138	594	-28	-440	-385	-249
Net Cash Flow from Financing Activities	-792	-3,099	-383	3,079	575	-753	394	-1,539	124	575	10	-401	-402	-285
Free Cash Flow to Equity	-1,210	-781	140	1,542	-97	-1,761	-316	-1,467	179	121	-307	-100	-3,290	-121
Free Operating CF net dividend	-379	-3,939	-837	-397	-751	-1,097	-754	-241	20	-571	-286	238	-2,996	84
Free Operating CF	-367	-949	-182	-373	-708	-1,053	-736	-87	37	-548	-286	252	-2,973	121

Business Segment Analysis

FY End:

Mar 25

Strides Pharma Science Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical business (100.0%)₹ 242.50 Cr

Revenue / Sales

Pharmaceutical business (100.0%)₹ 4,565.34 Cr

Assets

Pharmaceutical business (100.0%)₹ 6,048.73 Cr

Operating Income

Pharmaceutical business (100.0%)₹ 607.20 Cr

Regional Segment Analysis

FY End:

Mar 25

Strides Pharma Science Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

North America (55.8%)₹ 2,450.57 CrEurope (22.6%)₹ 993.80 CrAfrica (10.5%)₹ 461.58 CrAustralia (10.0%)₹ 439.58 CrAsia (0.5%)₹ 22.55 CrIndia (0.4%)₹ 15.96 CrRest of the world (0.2%)₹ 7.64 Cr

Historical Segment Analysis

Track how Strides Pharma Science Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2012 Dec 31	2014 Mar 31	2025 Mar 31

Pharmaceutical business	301	947	242
Biotech Business	6	34	-

Frequently Asked Questions

What is the revenue of Strides Pharma Science Ltd.?

The latest trailing twelve month revenue of Strides Pharma Science Ltd. is ₹ 4,858.68 Cr, reflecting a 1-year growth of 6.43% and a 3-year CAGR of 9.62%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Strides Pharma Science Ltd.?

The latest trailing twelve month net profit (PAT) of Strides Pharma Science Ltd. is ₹ 556.19 Cr, with a 3-year earnings CAGR of 11.06%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Strides Pharma Science Ltd.?

The trailing twelve month EBITDA of Strides Pharma Science Ltd. is approximately ₹ 722.89 Cr (based on an operating margin of 14.88%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Strides Pharma Science Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Strides Pharma Science Ltd. is 60.34. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Strides Pharma Science Ltd.?

The debt-to-equity ratio of Strides Pharma Science Ltd. stands at 0.57. The interest coverage ratio is 4.05x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Strides Pharma Science Ltd.?

The estimated book value per share of Strides Pharma Science Ltd. is 337.26 (derived from a P/B ratio of 3.34 and market price of ₹ 1,126.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Strides Pharma Science Ltd.?

The trailing twelve month operating cash flow of Strides Pharma Science Ltd. is ₹ 539.16 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Strides Pharma Science Ltd. report consolidated or standalone financials?

Strides Pharma Science Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.